Vigilant Biosciences Names William Brodie as Chief Executive Officer

Vigilant Biosciences Names William Brodie as Chief Executive Officer August 7, 2018 FORT LAUDERDALE, Fla., Aug. 7, 2018 /PRNewswire/ — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of oral and throat cancer, today announced the appointment of William “Bill” Brodie as Chief Executive Officer. Bill brings

Vigilant Biosciences Commences Studies of Oral Cancer Test

Vigilant Biosciences Commences Studies of Oral Cancer Test June 26, 2017 Vigilant Biosciences Inc, Fort Lauderdale, Fla, has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its premarket regulatory submission to FDA. Vigilant Biosciences’ initial clinical study is designed to validate performance and evaluate implementation of the OncAlert

Fort Lauderdale biotech firm gets federal grant for oral cancer study

Fort Lauderdale biotech firm gets federal grant for oral cancer study June 14, 2017 Fort Lauderdale-based Vigilant Biosciences, which has developed dental and lab toolkits for early detection of oral cancer, has been awarded part of a multi-million dollar grant for a study from the National Institutes of Health. The five-year study will enroll 300

Vigilant Biosciences Announces Grant Award from National Institutes of Health

Vigilant Biosciences Announces Grant Award from National Institutes of Health June 13, 2017 Fort Lauderdale, FLA. Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as part of a multi-million dollar grant from the National

Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert™ Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting

Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert™ Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting June 21, 2017 Fort Lauderdale, Fla. and WASHINGTON and PARIS Company to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical

Tests May Detect Oral Cancer Earlier

Tests May Detect Oral Cancer Earlier June 2, 2017 Oral and throat cancers can be life-threatening, and their frequency seems to be increasing. Now, two tests that are simple, painless and noninvasive can often detect them at very early stages when they can often be treated successfully. Both were developed here in South Florida. When

Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay

Vigilant Biosciences Launches Clinical Studies of Oral Cancer Assay May 12, 2017 Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and Drug Administration (FDA). The clinical studies are designed to validate the performance and evaluate the implementation of the OncAlert

Clinical Lab Trends for 2017

Clinical Lab Trends for 2017 May 12, 2017 Oral cancer – including cancers of the mouth and throat – is an area that is attracting new attention from the diagnostic community – this time with the help of dentists. New, promising technologies are making it easier for dental and medical professionals to detect oral cancer

Oral Cancer Tests

Oral Cancer Tests May 12, 2017 The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark. The tests are based on technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker,

Number To Know…1,000

Number To Know…1,000 May 12, 2017 Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test. Source: Medtech Insight Back to News

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2